Trial Profile
A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biogen
- 09 May 2014 New trial record